These studies will test the hypothesis that with oncogenic transformation the secretion of lysosomal proteases by transformed cells results from alterations in carbohydrate structure and/or placement on the glycoproteins. We plan to investigate the possible relationship between carbohydrate structure and protease secretion by the following approaches. First, Cathepsin B, Cathepsin D, and/or Beta-glucuronidase will be isolated from the medium of transformed cells and will be compared to similar fractions secreted by nontransformed, chloroquine-treated cells with respect to structure, number, and location of oligosaccharide moieties. We are interested in: (1) determining whether the protease from transformed cells lack the mannose-6-PO?4? recognition marker required for lysosomal localization, and/or whether they possess carbohydrate structures related to those of secretory glycoproteins; (2) studying the mannose-6-PO?4? receptor protein, in normal and transformed cells, with respect to cellular distribution, localization, and carbohydrate-binding properties; and (3) investigating the effects of alterations in oligosaccharides on the intracellular processing and transport of the lysosomal proteases. The functional significance of the alterations in carbohydrate moieties of the glycoproteins in transformed cells has not been investigated. Loss or modification of the mannose-6-PO?4? recognition marker of lysosomal enzymes might result in their aberrant accumulation in the extracellular milieu where they could act upon the surfaces and connective tissue stroma of tumor cells. Therefore, it is important to determine whether neoplastic cells produce altered forms of lysosomal proteases which are not recognized by the usual cellular recognition system responsible for """"""""routing"""""""" the enzymes to lysosomes. We have found that virus-transformed fibroblasts, in contrast to normal cells, exhibit increased membrane protease activity as measured by the degradation of fibronectin, laminin, and collagen (type IV). The enzyme responsible for the degradation of fibronectin is a metalloendoprotease based on product analyses and inhibitor studies. Presently, the enzyme(s) responsible for the degradation of laminin and collagen has not been characterized. (A)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA034918-03
Application #
3172728
Study Section
Pathobiochemistry Study Section (PBC)
Project Start
1983-03-01
Project End
1986-02-28
Budget Start
1985-03-01
Budget End
1986-02-28
Support Year
3
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Howard University
Department
Type
Schools of Medicine
DUNS #
056282296
City
Washington
State
DC
Country
United States
Zip Code
20059
Olden, K; Newton, S A; Nagai, T et al. (1992) The use of novel antineoplastic agents to inhibit the growth and metastasis of malignant melanoma and other cancers. Pigment Cell Res Suppl 2:219-33
Oredipe, O A; White, S L; Grzegorzewski, K et al. (1991) Protective effects of swainsonine on murine survival and bone marrow proliferation during cytotoxic chemotherapy. J Natl Cancer Inst 83:1149-56
White, S L; Nagai, T; Akiyama, S K et al. (1991) Swainsonine stimulation of the proliferation and colony forming activity of murine bone marrow. Cancer Commun 3:83-91
Mohla, S; White, S; Grzegorzewski, K et al. (1990) Inhibition of growth of subcutaneous xenografts and metastasis of human breast carcinoma by swainsonine: modulation of tumor cell HLA class I antigens and host immune effector mechanisms. Anticancer Res 10:1515-22
Olden, K; White, S L; Mohla, S et al. (1989) Experimental approaches for the prevention of hematogenous metastasis. Oncology (Williston Park) 3:83-91;discussion 95, 98-100
Newton, S A; White, S L; Humphries, M J et al. (1989) Swainsonine inhibition of spontaneous metastasis. J Natl Cancer Inst 81:1024-8
Grzegorzewski, K; Newton, S A; Akiyama, S K et al. (1989) Induction of macrophage tumoricidal activity, major histocompatibility complex class II antigen (Iak) expression, and interleukin-1 production by swainsonine. Cancer Commun 1:373-9
Mohla, S; Humphries, M J; White, S L et al. (1989) Swainsonine: a new antineoplastic immunomodulator. J Natl Med Assoc 81:1049-56
White, S L; Schweitzer, K; Humphries, M J et al. (1988) Stimulation of DNA synthesis in murine lymphocytes by the drug swainsonine: immunomodulatory properties. Biochem Biophys Res Commun 150:615-25
Olden, K; Mohla, S; Newton, S A et al. (1988) Use of antiadhesive peptide and swainsonine to inhibit metastasis. Ann N Y Acad Sci 551:421-41;discussion 441-2

Showing the most recent 10 out of 21 publications